The investment case for Dyne Therapeutics (NASDAQ: DYN ) rests on its trans‑TfR1 Fab technology platform (the “FORCE” platform) that they claim delivers its AOC (antibody-oligonucleotide conjugate) medicines deep into cardiac and skeletal muscles. This differentiates it from a group of peers who have the medicine but doMr Arunangshu Das is a software engineer, a finance and billing architect, and an active investor and entrepreneur. He is developing Tranzoro Investments to fill a critical lacunae - to help ...